Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993

L A Emens; S Adams; C H Barrios; V Diéras; H Iwata; S Loi; H S Rugo; A Schneeweiss; E P Winer; S Patel; V Henschel; A Swat; M Kaul; L Molinero; S Patel; S Y Chui; P Schmid

doi:10.1016/j.annonc.2021.10.002

Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993

Ann Oncol. 2021 Dec;32(12):1650. doi: 10.1016/j.annonc.2021.10.002. Epub 2021 Nov 2.

Authors

L A Emens¹, S Adams², C H Barrios³, V Diéras⁴, H Iwata⁵, S Loi⁶, H S Rugo⁷, A Schneeweiss⁸, E P Winer⁹, S Patel¹⁰, V Henschel¹¹, A Swat¹², M Kaul¹³, L Molinero¹⁴, S Patel¹⁵, S Y Chui¹⁰, P Schmid¹⁶

Affiliations

¹ University of Pittsburgh Medical Center Hillman Cancer Center and Department of Medicine, Pittsburgh, USA. Electronic address: emensla@upmc.edu.
² Breast Cancer Center, and Department of Medicine, New York University Langone Health, Perlmutter Cancer Center, New York, USA.
³ Oncology Clinics Group, Centro de Pesquisa Clínica, HSL, PUCRS, Porto Alegre, Brazil.
⁴ Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.
⁵ Breast Cancer Oncology Department, Aichi Cancer Center Hospital, Nagoya, Japan.
⁶ Translational Breast Cancer Genomics and Therapeutics Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia.
⁷ Department of Medicine, University of California San Francisco Comprehensive Cancer Center, San Francisco, USA.
⁸ National Center for Tumor Diseases, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany.
⁹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
¹⁰ Product Development Oncology, Genentech, Inc., South San Francisco, USA.
¹¹ Product Development Data Science, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
¹² Product Development Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
¹³ Product Development Safety, Genentech, Inc., South San Francisco, USA.
¹⁴ Oncology Biomarker Development, Genentech, Inc., South San Francisco, USA.
¹⁵ Product Development Data Sciences, Genentech, Inc., South San Francisco, USA.
¹⁶ Department of Cancer Medicine, Barts Cancer Institute, Queen Mary University London, London, UK.

PMID: 34740469
DOI: 10.1016/j.annonc.2021.10.002

No abstract available

Publication types

Published Erratum